Modulation of Molecular Biomarker Expression in Response to Chemotherapy in Invasive Ductal Carcinoma

Table 1

Clinical and pathological characteristics of the patients.

Characteristics	N	%
Overall series of patients	30	100
Mean age = 45 (range: 31–56 years)
Age < 45	16	53.33
Age ≥ 45	14	46.66
Menopausal status
Pre	10	33.33
Post	20	66.66
Histological diagnosis
Invasive ductal carcinoma	26	86.66
Invasive lobular carcinoma	2	6.66
Other subtypes	2	6.66
Tumor size
≤2 cm	12	40
>2 cm	18	60
Stage
I	11	36.33
II and III	19	63.66
Lymph node involvement
Negative	20	66.66
Positive	10	33.33
Nuclear grade
I	4	13.33
II	16	53.33
III	10	33.33
Receptor status
	16	53.33
	14	46.66
Immunohistochemical profile
Luminal A/B; Basal-like	16; 14	53.33; 46.66
Mean follow-up = 3 years

N: number of subjects; includes mucinous and papillary carcinomas; ER: estrogen receptor; luminal A: HER⁺, ER⁺/PR⁺; luminal B: HER2⁻/ER⁺/PR⁺; basal-like: HER2⁻, ER⁻/PR⁻.